Abstract
A search for poly(ADP-ribose) polymerase-1 inhibitors by virtual screening of a chemical compound database and a subsequent experimental verification of their activities have been performed. It was shown that the most efficient method to predict inhibitory properties implies a combinatorial approach joining molecular docking capabilities with structural filtration. Among more than 300000 low molecular chemical compounds, 9 PARP1 inhibitors were revealed; the most active ones, namely, STK031481, STK056130, and STK265022, displayed biological effect at a micromolar concentration (IC50 = 2.0, 1.0, and 2.6 μM, respectively).
Similar content being viewed by others
References
Chambon P., Weill J.D., Mandel P. 1963. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 11, 39–43.
D’Amours D., Desnoyers S., D’silva I., Poirier G.G. 1999. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342, 249–268.
Caldecott K.W., Aoufouchi S., Johnson P., Shall S. 1996. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular ‘nicksensor’ in vitro. Nucleic Acids Res. 24, 4387–4394.
Masson M., Niedergang C., Schreiber V., Muller S., Menissier-de Murcia J., de Murcia G. 1998. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell Biol. 18, 3563–3571.
Godon C., Cordelieres F.P., Biard D., Giocanti N., Megnin-Chanet F., Hall J., Favaudon V. 2008. PARP inhibition versus PARP-1 silencing: Different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res. 36, 4454–4464.
Sukhanova M.V., Lavrik O.I., Khodyreva S.N. 2004. Poly(ADP-ribose) polymerase-1: A regulator of protein-nucleic acid interactions in processes responding to genotoxic impact. Mol. Biol. (Moscow). 38, 706–717.
Timinszky G., Till S., Hassa P.O., Hothorn M., Kustatscher G., Nijmeijer B., Colombelli J., Altmeyer M., Stelzer E.H., Scheffzek K., Hottiger M.O., Ladurner A.G. 2009. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nature Struct. Mol. Biol. 16, 923–929.
Ahel D., Horejsi Z., Wiechens N., Polo S.E., Garcia-Wilson E., Ahel I., Flynn H., Skehel M., West S.C., Jackson S.P., Owen-Hughes T., Boulton S.J. 2009. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science. 325, 1240–1243.
Gottschalk A.J., Timinszky G., Kong S.E., Jin J., Cai Y., Swanson S.K., Washburn M.P., Florens L., Ladurner A.G., Conaway J.W., Conaway R.C. 2009. Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc. Natl. Acad. Sci. U.S.A. 106, 13770–13774.
Gatti L., Zunino F. 2005. Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 111, 127–148.
Borst P., Rottenberg S., Jonkers J. 2008. How do real tumors become resistant to cisplatin? Cell Cycle. 7, 1353–1359.
Drew Y., Plummer, R. 2009. PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Update. 12, 153–156.
Schreiber V., Dantzer. F., Ame J.C., de Murcia G. 2006. Poly(ADP-ribose): novel functions for an old molecule. Nature Rev. Mol. Cell Biol. 7, 517–528.
White A.W., Almassy R., Calvert A.H., Curtin N.J., Griffin R.J., Hostomsky Z., Maegley K., Newell D.R., Srinivasan S., Golding B.T. 2000. Resistance-modifying agents: 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J. Med. Chem. 43, 4084–4097.
Stroganov O.V., Novikov F.N., Stroylov V.S., Kulkov V., Chilov G.G. 2008. Lead finder: An approach to improve accuracy of protein ligand docking, binding energy estimation, and virtual screening. J. Chem. Inf. Model. 48, 2371–2385.
STK library. 2007. Vitas-M Laboratory. http://www.vitasmlab.com/.
Sukhanova M.V., Khodyreva S.N., Lavrik O.I. 2004. Poly(ADP-ribose) polymerase 1 inhibits strand-displacement DNA synthesis catalyzed by DNA polymerase β. Biochemistry (Moscow). 69, 686–698.
Neubig R.R., Spedding M., Kenakin T., Christopoulos A. 2003. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 55, 597–606
Kamanaka Y., Kondo K., Ikeda Y., Kamoshima W., Kitajima T., Suzuki Y., Nakamura Y., Umemura K. 2004. Neuroprotective effects of ONO-1924H, an inhibitor of poly ADP-ribose polymerase (PARP), on cytotoxicity of PC12 cells and ischemic cerebral damage. Life Sci. 76, 151–162.
Menear K.A., Adcock C., Boulter R., Cockcroft X.L., Copsey L., Cranston A., Dillon K.J., Drzewiecki J., Garman S., Gomez S., Javaid H., Kerrigan F., Knights C., Lau A., Loh V.M.Jr., Matthews I.T., Moore S., O’Connor M.J., Smith G.C., Martin N.M. 2008. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 51, 6581–6591.
Novikov F.N., Stroylov V.S., Stroganov O.V., Chilov G.G. 2010. Improving performance of docking-based virtual screening by structural filtration. J. Mol. Model. 16, 1223–1230.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © A.L. Zakharenko, M.V. Sukhanova, S.N. Khodyreva, F.N. Novikov, V.S. Stroylov, D.K. Nilov, G.G. Chilov, V.K. Svedas, O.I. Lavrik, 2011, published in Molekulyarnaya Biologiya, 2011, Vol. 45, No. 3, pp. 565–569.
Rights and permissions
About this article
Cite this article
Zakharenko, A.L., Sukhanova, M.V., Khodyreva, S.N. et al. Improved procedure of the search for poly(ADP-Ribose) polymerase-1 potential inhibitors with the use of the molecular docking approach. Mol Biol 45, 517–521 (2011). https://doi.org/10.1134/S0026893311030228
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893311030228